Journal profile · Medicine-Radiology, Nuclear Medicine and Imaging
Advances in Radiation Oncology
ISSN 2452-1094 · Elsevier · United States
Advances in Radiation Oncology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.9 (journal website); fully open access; APC about USD 2,500; median 166 days to acceptance (104 articles, last 24 months); acceptance rate 44% (journal website); 234 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Advances in Radiation Oncology is published by Elsevier and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Advanced Radiotherapy Techniques, Advances in Oncology and Radiotherapy and Effects of Radiation Exposure, together about 33.7% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
An official journal of the American Society for Radiation OncologyAdvances in Radiation Oncology is a peer reviewed, wide-ranging open access journal from the American Society for Radiation Oncology (ASTRO). Included in PubMed Central, Advances complements the research in the International Journal of Radiation Oncology • Biology • Physics and Practical Radiation Oncology. The mission of Advances in Radiation Oncology is to provide original clinical research aimed at improving the lives of people living with cancer and other diseases treated with radiation therapy. The purpose of Advances is to provide information for clinicians who use radiation therapy by publishing:Clinical trial reports and reanalyses.Basic science original reports.Manuscripts examining health services research, comparative and cost effectiveness research, and systematic reviews.Case reports documenting unusual problems and solutions.High quality multi and single institutional series, as well as other novel retrospective hypothesis generating series.Timely critical reviews on important topics in radiation oncology, such as side effects.Articles reporting the natural history of disease and patterns of failure, particularly as they relate to treatment volume delineation.Articles on safety and quality in radiation therapy.Essays on clinical experience.Articles on practice transformation in radiation oncology, in particular:Aspects of health policy that may impact the future practice of radiation oncology.How information technology, such as data analytics and systems innovations, will change radiation oncology practice.Articles on imaging as they relate to radiation therapy treatment.Advances is a gold open access journal, so authors, readers and patients have free access to all articles. All work published by this journal is thoroughly peer reviewed by the editorial board and expert reviewers in radiation oncology. Authors retain copyright of their articles and reuse is governed under a Creative Commons license so that readers can freely and easily share information. Learn more about the types of articles sought by the editorial team.Disclaimer The views expressed in Advances in Radiation Oncology (the "Journal") are those of the individual authors and are not necessarily those of the American Society for Radiation Oncology (ASTRO) or the Publisher. The information contained in the Journal is not medical advice and is not intended to replace the judgment of a practitioner with respect to particular patients, procedures, or practice. No responsibility is assumed by the Publisher nor by the Society for any injury and/or damage to persons or property as a result of (i) any actual or alleged libellous statements or infringement of intellectual property or privacy rights, (ii) product liability or negligence; (iii) an author's statements or other materials; or (iv) the use or operation of any ideas, instructions, procedures, products, or methods contained in the Journal. Due to rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should always be made. In any jurisdiction that does not permit such a disclaimer of liability, the liability of ASTRO and the Publisher shall be limited to the greatest extent allowed by applicable law.Publication of an advertisement in the Journal does not constitute on the part of the Publisher or the Society a guarantee or endorsement of the quality or value of the advertised products or services described therein or of any of the representations or the claims made by the advertisers with respect to such products or services.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Radiology, Nuclear Medicine and Imaging
Editor-in-chief Rachel JimenezPublisher website
Editorial board by country: none in mainland China; most named United States 50, Germany 5, Canada 4, South Africa 2, Italy 1 (62 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Advanced Radiotherapy TechniquesPhysics and Astronomy17.7%
- Advances in Oncology and RadiotherapyMedicine9.2%
- Effects of Radiation ExposureMedicine6.9%
- Prostate Cancer Diagnosis and TreatmentMedicine6.2%
- Management of metastatic bone diseaseMedicine5.7%
- Radiation Therapy and DosimetryMedicine5.2%
- Brain Metastases and TreatmentMedicine4.8%
- Lung Cancer Diagnosis and TreatmentMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Radiology, Nuclear Medicine & Medical Imaging | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 2.9Publisher website ·
- CiteScore 2026-06
- 4.2LetPub ·
- CiteScore (publisher)
- 4.2Publisher website ·
- SJR 2026-06
- 0.87LetPub ·
- SNIP 2026-06
- 0.91LetPub ·
- h-index
- 52OpenAlex ·
- i10-index
- 617OpenAlex ·
- 2-year mean citedness
- 1.62OpenAlex ·
- Self-citation rate
- 6.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 177LetPub ·
Articles by year OpenAlex count · 1,950 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 200 | 200 | 16 |
| 2025 | 234 | 234 | 257 |
| 2024 | 224 | 224 | 791 |
| 2023 | 215 | 215 | 1,544 |
| 2022 | 245 | 245 | 2,038 |
| 2021 | 214 | 214 | 2,221 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
166 daysMedian, submission to acceptance · P25–P75 119 days – 222 days
- Acceptance to online
- median 21 days (104 articles)
- Submission to online
- median 218 days
- Sample
- 104 articles with submission and acceptance dates (455 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 weeksLetPub ·
- Acceptance rate (publisher)
- 44%Publisher website ·
- Submission to first decision
- 16 daysPublisher website ·
- First decision after review
- 70 daysPublisher website ·
- Submission to acceptance
- 150 daysPublisher website ·
- Submission to publication (journal-reported)
- about 29 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,500 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,500 / EUR 2,340 / GBP 2,000 / JPY 310,080 | — | — | |
| LetPub | USD 2,500 | Yes | — | |
| Publisher website | USD 2,500 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
Article Publishing Charge (APC): USD 2,500 (excluding taxes). Review this journal’s open access policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- United States
- Language
- English
- ISSN
- 2452-1094
- Society / sponsor
- American Society for Radiation Oncology
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Advances in Radiation Oncology
What CAS zone is Advances in Radiation Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Advances in Radiation Oncology is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology / Radiology, Nuclear Medicine & Medical Imaging. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Advances in Radiation Oncology?
The journal's website gives an impact factor of 2.9; this is the journal's own figure, as LetPub lists none for it; CiteScore 4.2, h-index 52.
How long does peer review take at Advances in Radiation Oncology?
Based on the dates recorded on 104 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 166 days (interquartile range 119–222 days); authors report an average review time of about 6 weeks; the journal's website gives an acceptance rate of 44%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Advances in Radiation Oncology based?
Of the 62 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (50), Germany (5) and Canada (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Advances in Radiation Oncology?
According to LetPub and DOAJ records, Advances in Radiation Oncology is indexed in ESCI, Scopus and DOAJ.
Is Advances in Radiation Oncology open access, and what is the APC?
Advances in Radiation Oncology is a fully open-access journal. APC about USD 2,500.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .